Histrelin Research

Serilmez M, Abuelrub A, Erol I, Durdaği S

The COVID-19 pandemic caused by SARS-CoV-2 necessitated rapid development of effective therapeutics, prompting this study to identify potential inhibitors targeting key viral and host proteins: RNA-dependent RNA polymerase (RdRp), main protease (Mpro), transmembrane serine protease 2 (TMPRSS2), a...

Chen Y, Lu W, Liao R, Zhang X, Chen W, Wang J et al.

Long-acting Gonadotropin-releasing hormone analogs(GnRHa), including leuprolide, goserelin, histrelin, buserelin, triptorelin, have been widely used for a variety of diseases including prostate cancer, breast cancer, endometriosis, uterine leiomyomas, and central precocious puberty (CPP). However...

Boumil MM, Beninger P

US v. Skrmetti is a legal case currently pending before the US Supreme Court that addresses the constitutionality of a Tennessee statute that prohibits gender-affirming medical care for transgender individuals who have not yet reached the legal age of adulthood, and who are diagnosed with gender ...

Hafron J, Hong A, Ryan MJ, Romdhani H, Kinkead F, Flanders SC et al.

Androgen deprivation therapy (ADT) is standard for advanced prostate cancer. Relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, is the only oral ADT, with limited real-world data on therapy persistence and adherence. This retrospective study evaluates persistence and adherenc...

Marpuri I, Geffner ME, Chao LC

Histrelin acetate implant (HI) is an approved treatment option for children with central precocious puberty. Implant duration has been reported to surpass the recommended replacement interval of 1-2 years. Implant breakage is a known potential adverse effect during the extraction procedure. Howev...

Bryant B, Stoops MA, Conaghan J, Williams J, Campbell-Ward M, Wallace A et al.

A zoo-based, 11-year-old, uniparous southern black rhinoceros (Diceros bicornis minor) failed to conceive after weaning a calf. Behavioral observation and fecal progestagen monitoring confirmed irregular estrous cycles. Serial transrectal reproductive ultrasound examination revealed the cause to ...

Rodrigues LT, Segabinazzi L, Frasson M, Dell'Aqua C, Carmo MT, Takahira RK et al.

Although protocols for superovulation have been described in horses, this technique has been discouraged due to the low embryo recovery rates in superovulated mares. The reason for these poor results is poorly understood, but the formation of a blood clot in the ovulation fossa following ovulatio...

Ding S, Brownlee BJ, Parate K, Pola CC, Chen B, Hostetter JM et al.

Highly sensitive vertically aligned carbon nanotube arrays (VANTAs) interdigitated electrode (IDE) arrays are developed for electrochemical biosensing of two cytokines (i.e., interleukin-10 (IL-10) and interferon-gamma (IFN-γ)) that are useful for early detection Johne's disease (Bovine Par...

Patel S, Zhu K, Dave CV, Ghajar M, Zhang Y, Saraiya B et al.

Gonadotropin-releasing hormone (GnRH) antagonists and agonists are cornerstone treatments in prostate cancer. However, evidence regarding the comparative cardiovascular safety of these drugs from clinical trials is inconclusive. The objective of this study was to systematically assess the risk of...

Preston MA, Ebrahimi R, Hong A, Bobbili P, Desai R, Duh MS et al.

Intermittent androgen deprivation therapy (iADT) alleviates some side effects of continuous (c) ADT in patients with prostate cancer (PC), but its relative impact on ADT-associated comorbidities is uncertain. We assessed real-world use of iADT and cADT and associated risk of cardiovascular and en...

Ruplin A, Segal E, McFarlane T

The objective of this review is to provide an overview of common drug-drug interactions (DDIs) associated with prostate cancer treatments and outline recommendations for managing polypharmacy.A literature search of PubMed, Embase, and CINAHL was carried out to identify pharmacokinetic and pharmac...

Breidbart E, Breidbart E, Ilkowitz J, Regelmann MO, Ashraf AP, Gourgari E et al.

Gonadotropin releasing hormone analogs (GnRHas) are used for treatment of precocious puberty. Over the last decade, several new formulations have been approved.The Drugs and Therapeutics Subcommittee of the Pediatric Endocrine Society (PES) undertook a review to ascertain the current treatment op...

Barrera E, Locks R, Kremen J, Yu R

Fertility preservation (FP) is an important aspect of the care of transgender patients in whom Gender Affirming Medical Treatment (GAT) may begin before puberty is completed. While there are overall few studies that can be used to guide conversations about long-term effects of GAT, there are conc...

Mak A, Hwang R, Nace G, Allukian M, Nance ML

Determine procedural outcomes and identify changing trends of utilization among patients undergoing histrelin implantation at a large pediatric tertiary care center over 15 y.Retrospective review of all patients undergoing histrelin implantation between January 2008 and April 2022.A tot...

Pine-Twaddell E, Newfield RS, Marinkovic M

Histrelin implant (HI) is a gonadotropin-releasing hormone agonist (GnRHa) used in pediatrics to treat central precocious puberty (CPP) and for pubertal suppression in transgender/non-binary (TG/NB) youth with gender dysphoria. HI is designed for annual removal/replacement; however, effectiveness...

Ray LA, Eckert GJ, Eugster EA

The histrelin implant has been used to treat central precocious puberty (CPP) for more than 15 years. Although approved for annual use, limited published reports suggest that a single implant is efficacious well beyond a year. Our objective was to report our long-term experience using a sing...

Popovic J, Geffner ME, Rogol AD, Silverman LA, Kaplowitz PB, Mauras N et al.

Gonadotropin-releasing hormone agonists (GnRHa's) are the standard treatment for children with central precocious puberty (CPP). We aim to present data on available GnRHa options with an easy-to-review table and discuss factors that influence treatment selection. Five GnRHa's are currently FDA-ap...

Raja T, Sud R, Addla S, Sarkar KK, Sridhar PS, Talreja V et al.

Androgen deprivation therapy (ADT) using gonadotropin-releasing hormone agonist (s) (GnRH-A) remains the backbone of advanced prostate cancer treatment. In this review, we assessed the efficacy, safety, and convenience of administration of various GnRH-A. All GnRH-A (goserelin, triptorelin, buser...

Villalta D, Quintos JB

Gonadotropin-releasing hormone analogues (GnRHas) are an effective treatment to address the compromise in height potential seen in patients with central precocious puberty. There is no evidence in the literature of a single GnRHa used for longer than 2 years before being removed or replaced. We d...